Literature DB >> 23525238

PD-L1/PD-1 Co-Stimulation, a Brake for T cell Activation and a T cell Differentiation Signal.

Therese Liechtenstein1, Ines Dufait, Christopher Bricogne, Alessio Lanna, Joeri Pen, Karine Breckpot, David Escors.   

Abstract

For T cell activation, three signals have to be provided from the antigen presenting cell; Signal 1 (antigen recognition), signal 2 (co-stimulation) and signal 3 (cytokine priming). Blocking negative co-stimulation during antigen presentation to T cells is becoming a promising therapeutic strategy to enhance cancer immunotherapy. Here we will focus on interference with PD-1/PD-L1 negative co-stimulation during antigen presentation to T cells as a therapeutic approach. We will discuss the potential mechanisms and the therapeutic consequences by which interference/inhibition with this interaction results in anti-tumour immunity. Particularly, we will comment on whether blocking negative co-stimulation provides differentiation signals to T cells undergoing antigen presentation. A major dogma in immunology states that T cell differentiation signals are given by cytokines and chemokines (signal 3) rather than co-stimulation (signal 2). We will discuss whether this is the case when blocking PD-L1/PD-1 negative co-stimulation.

Entities:  

Keywords:  CD80; Cancer; Co-stimulation; Dendritic cell; Immunotherapy; PD-1; PD-L1

Year:  2012        PMID: 23525238      PMCID: PMC3605779          DOI: 10.4172/2155-9899.S12-006

Source DB:  PubMed          Journal:  J Clin Cell Immunol


  83 in total

1.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

2.  siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells.

Authors:  Willemijn Hobo; Frans Maas; Niken Adisty; Theo de Witte; Nicolaas Schaap; Robbert van der Voort; Harry Dolstra
Journal:  Blood       Date:  2010-08-03       Impact factor: 22.113

3.  Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

Authors:  Qing Zhou; Meghan E Munger; Steven L Highfill; Jakub Tolar; Brenda J Weigel; Megan Riddle; Arlene H Sharpe; Daniel A Vallera; Miyuki Azuma; Bruce L Levine; Carl H June; William J Murphy; David H Munn; Bruce R Blazar
Journal:  Blood       Date:  2010-06-22       Impact factor: 22.113

Review 4.  T cell defined tumor antigens.

Authors:  B J Van den Eynde; P van der Bruggen
Journal:  Curr Opin Immunol       Date:  1997-10       Impact factor: 7.486

Review 5.  Role of PD-1 in regulating acute infections.

Authors:  Keturah E Brown; Gordon J Freeman; E John Wherry; Arlene H Sharpe
Journal:  Curr Opin Immunol       Date:  2010-04-27       Impact factor: 7.486

6.  B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.

Authors:  A I Chapoval; J Ni; J S Lau; R A Wilcox; D B Flies; D Liu; H Dong; G L Sica; G Zhu; K Tamada; L Chen
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

7.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

Review 8.  Therapeutic intervention in cancer and chronic viral infections: antibody mediated manipulation of PD-1/PD-L1 interaction.

Authors:  Priya Sakthivel; Marcus Gereke; Dunja Bruder
Journal:  Rev Recent Clin Trials       Date:  2012-02

9.  Enhancing SIV-specific immunity in vivo by PD-1 blockade.

Authors:  Vijayakumar Velu; Kehmia Titanji; Baogong Zhu; Sajid Husain; Annette Pladevega; Lilin Lai; Thomas H Vanderford; Lakshmi Chennareddi; Guido Silvestri; Gordon J Freeman; Rafi Ahmed; Rama Rao Amara
Journal:  Nature       Date:  2008-12-10       Impact factor: 49.962

10.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

View more
  21 in total

1.  Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.

Authors:  Therese Liechtenstein; Noemi Perez-Janices; Idoia Blanco-Luquin; Cleo Goyvaerts; Julia Schwarze; Ines Dufait; Alessio Lanna; Mark De Ridder; David Guerrero-Setas; Karine Breckpot; David Escors
Journal:  Oncoimmunology       Date:  2014-07-03       Impact factor: 8.110

2.  Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activation.

Authors:  Antonio Sorrentino; Ayse Nur Menevse; Tillmann Michels; Valentina Volpin; Franziska Christine Durst; Julian Sax; Maria Xydia; Abir Hussein; Slava Stamova; Steffen Spoerl; Nicole Heuschneider; Jasmin Muehlbauer; Katharina Marlene Jeltsch; Anchana Rathinasamy; Melanie Werner-Klein; Marco Breinig; Damian Mikietyn; Christian Kohler; Isabel Poschke; Sabrina Purr; Olivia Reidell; Catarina Martins Freire; Rienk Offringa; Claudia Gebhard; Rainer Spang; Michael Rehli; Michael Boutros; Christian Schmidl; Nisit Khandelwal; Philipp Beckhove
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

3.  Olfactory ecto-mesenchymal stem cells possess immunoregulatory function and suppress autoimmune arthritis.

Authors:  Ke Rui; Zhijiang Zhang; Jie Tian; Xiang Lin; Xiaohui Wang; Jie Ma; Xinyi Tang; Huaxi Xu; Liwei Lu; Shengjun Wang
Journal:  Cell Mol Immunol       Date:  2015-09-21       Impact factor: 11.530

Review 4.  Gene therapy in corneal transplantation.

Authors:  Yureeda Qazi; Pedram Hamrah
Journal:  Semin Ophthalmol       Date:  2013 Sep-Nov       Impact factor: 1.975

5.  Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.

Authors:  David Escors
Journal:  New J Sci       Date:  2014-01-05

6.  Lentiviral vectors for cancer immunotherapy and clinical applications.

Authors:  Therese Liechtenstein; Noemi Perez-Janices; David Escors
Journal:  Cancers (Basel)       Date:  2013-09       Impact factor: 6.639

7.  Corneal Allograft Rejection: Immunopathogenesis to Therapeutics.

Authors:  Yureeda Qazi; Pedram Hamrah
Journal:  J Clin Cell Immunol       Date:  2013-11-20

8.  TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma.

Authors:  Shixiang Bao; Xiaopei Jiang; Shuai Jin; Peipei Tu; Jingtao Lu
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

Review 9.  Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?

Authors:  David Escors; Therese Liechtenstein; Noemi Perez-Janices; Julia Schwarze; Ines Dufait; Cleo Goyvaerts; Alessio Lanna; Frederick Arce; Idoia Blanco-Luquin; Grazyna Kochan; David Guerrero-Setas; Karine Breckpot
Journal:  Oncoimmunology       Date:  2013-09-12       Impact factor: 8.110

Review 10.  The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.

Authors:  Li Shi; Shaohua Chen; Lijian Yang; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2013-09-30       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.